|
A EUROPEAN TECHNOLOGY PLATFORM |
Working
Group 1 “Basic Research and Mapping”
2d
meeting, Brussels, 28 November 2005
Final, 20 December 2005
|
BBSRC / P-P. Pastoret (Chair) AFSSA / F. Moutou BVL / R. Kroker CEVA
/ E. Balla (for B. Kadra) CIRAD / D. Martinez CODA-CERVA / F. Koenen CODA-CERVA / K. De Clercq CVO Slovakia / P. Cery
(for J. Bires) Friedrich Loeffer Institut / Th.C.
Mettenleiter IAH-Pirbright UK / J. Bashiruddin
(for D. Paton) Intervet / D. Goovaerts
(for D. Lütticken) London School of Pharmacy / O.
Alpar Merial / J-Ch. Audonnet National Veterinary Institute,
Sweden / F. Widen (for S. Belak) Pfizer AH / M.J. Witty Royal Veterinary College / Q.
McKellar Tierärztliche Hochschule Hannover
/ V. Moennig University of Edinburgh / I.
Morrison University of Plovdiv / A.
Arnaudov (for I. Minkov) |
IFAH-Europe / M. Chaton-Schaffner IFAH-Europe / H. Marion (minutes) Observer EC / B. Arbelot EC / I. Minguez-Tudela Trivarop / J. Vandeputte Apologies Bommeli / Ch. Schelp ESVV / J. Van Oirschot Facultad de Veterinaria Madrid /
J.M. Sanchez-Viscaino (Vice-chair) Fort Dodge / J. Plana Duran IZS Venezie-Italy / I. Capua London School of Hygiene and
Tropical Medicine / P. Roy OIE / A. Schudel University of Ghent / J. Vercuysse
(Observer) Pasteur Institute Paris / H. Bourhy (Observer) Pasteur Institute Paris / N. Tordo (Observer) IFAH-Europe / J. Scudamore
(consultant) IFAH-Europe / D. O’Brien
(Chair of the EB) |
Agenda
|
|
|
|
|
|
Sub-groups working
separately to propose priorities, focusing on diseases; definition of list of
diseases of High, Medium and Low Priority
|
Presentations of the
Propositions by the Chairmen of the different sub-groups
|
General Discussions
and Conclusions
|
Close of the Meeting
|
The second meeting of the Working Group (WG) was held in DG Research on Monday 28 November 2005. A total of 24 participants attended.
Dr H. Marion, project manager
in IFAH-Europe, welcomed the participants on behalf of Mr D O’Brien, Managing Director and Chairman of the Steering Council for the Platform.
He thanked the experts for
the work achieved during the first meeting of the WG and pointed out that the
chairmen of the 3 groups had met after the first meetings to coordinate the
achievements of the 3 groups.
This had enabled Jim
Scudamore to prepare a first draft of the SRA which had been circulated prior to
this meeting. H. Marion thanked warmly J. Scudamore for the impressive amount
of work already achieved.
He explained that the aim of
this meeting was to propose the priority topics that should be included in the
SRA.
After this meeting, the
chairmen will meet again to finalise the input from the 3 WGs.
There will be no further
meeting of the experts.
A new draft of the SRA will
then be broadly circulated in January, on which all Stakeholders and experts
will be asked to comment.
A Stakeholders meeting will
take place in mid-February in order to discuss and adopt the final draft of the
SRA, which will then be formally sent to the European Commission before the end
of March 2006.
H. Marion finally thanked the
European Commission, and in particular Dr I. Minguez-Tudela, for the continuous
support of the work of this Platform and for hosting the second WG meetings.
The chairman, Prof. P.-P.
Pastoret explained that this meeting should enable the experts to set up a
priority list and to identify the parameters for defining the priority topics.
He highlighted the need to
reach a consensus also between the 3 WGs and pointed out that the other 2 WGs
as well as the Stakeholders would input into the final SRA.
He suggested that the results
of the day’s discussion should result also in the drafting of 2 tables
including the priority topics and the parameters.
The draft of the SRA for “The
Innovative Medicines Initiatives (“human” medicinal field) was circulated to
the group for information.
Four presentations were given suggesting research issues and needs for
inclusion in the SRA. Details of the presentations are found on the ETPGAH web
site at http://www.ifah.be/europe/euplatform/platform.htm.
The topics covered were as follows:
Basic Research and
Immunology
Research needs for
developing countries
Research needs in
Epidemiology and Infectious Diseases
The participants acknowledged
the need over the next 10 years to foster a creative environment for basic
research and to stimulate investment in research, in particular in the fields
of molecular biology, fundamental immunology etc….
However, not all problems can
be solved and the SRA should be focused in order to maximise the efficiency of
future funding. It should also highlight the topics with a list of priorities,
and each topic should have a specific agenda.
It was recognised that the
topics should not only focus on immunology, but also on pharmaceuticals and
gaps in treatments, as well as the minor species minor uses issue.
The topics should highlight
the existing gaps and cover global, endemic, emerging and wildlife issues.
1) Generic needs Epidemio-surveillance
Immunological
toolbox
Wildlife
components
Animal
genomics
Entomology
Bioinformatics
& biostatistics
Infrastructure
Arthropod
vectors
Cell
biology
Target
challenge models
Training
ex histopathology, pharmaco-toxicology
Ethology-ecology
Creation
of a European “CDC” animal center
The following
remarks were raised:
-
not to forget pharmaceuticals /
parasiticides
-
need of pharmacology research
-
reliable diagnosis – molecular
aspects for diagnosis
-
genomics and pathogenomics
-
partnership between EU and
developing countries (DC)
-
education and training for DC
-
lack of a central institute for
epidemio-surveillance
-
wildlife reservoir
-
establishment of multinational
network
-
need for globally sort out new
technologies
-
delivery systems – mass applicable –
wildlife
-
sustainable use of antibiotics
2) Listing of
diseases
What is global,
what is endemic and what is emerging (incl. Exotic)?
a) vertical ASF
CSF – pestivirus
infections improved vaccine for wildlife
FMD
Rabies dog vaccine
in DC
BVD
Blue Tongue
West Nile
CBPP
Rift valley fever
Ruminant Pox
Salmonella
Campylobacter
Influenza
TSE
PPR
Mastitis
Tickborne disease
Sheep scab
Newcastle disease
African Horse Sickness
Q Fever
Coccidiosis
Trypanosomiasis
Chlamidyasis
Leishmaniosis
Borna disease
Brucellosis
Marek
Gumboro
Streptococcus suis
Swine cistycercosis
Tuberculosis
Paratuberculosis
b) Horizontal
Zoonotic impact
Specific impact on
Developing Countries
Host pathogen
interaction
Epidemiology
including resistance of pathogens
Immunology
Prevention
Diagnosis
Therapy
3/ Prioritisation
see Annexes 1, 3 & 4
The experts adopted the following lists:
list
of 1’ top priority topics
list
of “neglected zoonoses”
list of food-borne zoonosis, inluding
Salmonella, Campylobacter, E. Coli and Cryptosporidium
list
of “need for surveillance”
Actions:
The 4 “rapporteurs” on the 4 topics presented at the
beginning of the discussion were asked to provide to the chairman by
Wednesday 7 December one page on the rationale for the choice of the 14 top
priorities (within 10 days)
+ also economic impact from IFAH and/or from
Stakeholders